Masimo Corp. today gave an update on its long-term strategy during its 2025 Investor Day held at the company’s Irvine headquarters.
Among the updates were financial targets including compound annual growth rate (CAGR) of 7% to 10%, as well as operating margin of 30% by 2028.
“Masimo’s market leading position is driven by our mission to deliver innovations that empower clinicians and transform patient care,” Chief Executive Katie Szyman said in a statement.
Masimo also reaffirmed its previously announced 2025 financial guidance, including revenue of $1.51 billion to $1.53 billion, operating profit of between $412 million to $424 million and earnings per share between $5.40 to $5.55.
Shares in the company decreased 2.8% to $138.09 and a $7.4 billion market cap during regular trading (Nasdaq: MASI).
